SPYRE THERAPEUTICS INC (SYRE)
Health Care · biotechnology · NASDAQ
Spyre Therapeutics is developing next-generation, extended half-life antibodies and combination therapies aimed at redefining the standard of care for inflammatory bowel disease and immune-mediated conditions.
What SPYRE THERAPEUTICS INC does
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation, extended half-life antibody therapies for inflammatory bowel disease (IBD) and other immune-mediated conditions. The company utilizes a strategy of creating optimized monotherapies and fixed-dose combinations to improve potency, selectivity, and patient treatment experiences. Its primary development programs include targeting α4β7, TL1A, and IL-23, currently being evaluated in mid-stage clinical trials.
Themes: autoimmune diseases, inflammatory bowel disease (IBD), antibody therapeutics, pharmacokinetics optimization
Fundamentals
- Price$79.90 as of 2026-10-08 close
- Market cap$7.0B as of 2026-07-28 (share count; price 2026-10-08)
- 1-year return+351.9% 2025-10-08 close $17.68 → 2026-10-08 close $79.90
- P/En/a negative earnings
- ROE-21.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta1.71 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How SYRE compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SPYRE THERAPEUTICS INC looks technically
SPYRE THERAPEUTICS INC (SYRE) is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 238 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-06-09, breaking below its recent trading range. It is 27.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $94.65 | $94.65 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $68.01 | $68.01 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 84. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 238 trading days ago — a "golden cross", a bullish long-term signal | 238 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 18.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 34.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($77.05 to $95.27) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 15.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $110.17 | $110.17 |
|---|---|---|
| From the 52-week high | it is 27.5% below its 52-week high (its highest price of the past year) | -27.5% |
| Above the 52-week low | it is 403.8% above its 52-week low (its lowest price of the past year) | +403.8% |
| Below the 52-week high | it is 27.5% below its highest point of the past year | 27.5% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-09, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-09, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $318.75 (set on 2016-04-08) | $318.75 |
| Given back of the 52-week move | over the past year its closes ranged ($15.89 to $108.92), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $48.45 to $51.43. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 31.2% |
| From the all-time high | it is 74.9% below its all-time high | -74.9% |
| Nearest price level | it is trading 4.5% below a resistance level at $83.47 — a price it turned at twice since 2026-09-02, most recently on 2026-09-24. Since 2024-10-08 it has 14 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.5% |
| All-time low | its lowest closing price on record is $2.65 (set on 2023-06-21) | $2.65 |
| Above the all-time low | it is 2915.1% above its all-time low | +2,915% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 45th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.32 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.32 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $80.08 and $96.68 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $80.08 – $88.38 – $96.68 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 2.2 daily ranges above its 200-day average price (17.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.56× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.1% since the prior reading | +0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.05 toward sell |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.6% |
|---|---|---|
| Open gap | it gapped 13.9% below the previous close 30 sessions ago and has not traded back through the level it left behind at 107.36 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -13.9% |
| Gap filled | a 4.6% gap up opened on 2026-09-30 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 2 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.0 percentage points (the stock lost 12.0% while the market gained 1.0%) | -13.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 20.1 percentage points (the stock lost 16.2% while the market gained 3.8%) | -20.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 45.7 percentage points (the stock gained 63.1% while the market gained 17.5%) | +45.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 336.9 percentage points (the stock gained 351.9% while the market gained 15.0%) | +336.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.1% of the share price. | -16.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $75.19 — a volume-weighted average of daily closes over 189 sessions, not a true tick-by-tick VWAP. | +6.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $91.83 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -13.0% |
Price levels it has turned at before
SYRE last closed at $79.90 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $83.47 | Resistance | 4.5% above the last close | turned there twice · 2026-09-02 to 2026-09-24 |
| $75.49 | Support | 5.5% below the last close | turned there four times · 2026-04-13 to 2026-05-26 |
| $92.28 | Resistance | 15.5% above the last close | turned there three times · 2026-07-17 to 2026-09-08 |
| $95.40 | Resistance | 19.4% above the last close | turned there twice · 2026-08-14 to 2026-09-17 |
| $45.58 | Support | 43.0% below the last close | turned there twice · 2026-02-23 to 2026-03-17 |
| $35.19 | Support | 56.0% below the last close | turned there twice · 2025-12-11 to 2026-01-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $84.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $84.00 and $85.82 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.18 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$120.21 range $97.00 – $130.00; median $122.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SYRE
- Consensus EPS estimate-$0.8273 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.01742 from -$0.8099, on 2026-09-01, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial success and regulatory approval risks for experimental antibody therapies.","Dependence on the success of specific product candidates and platform technologies.","Significant accumulated deficits and the requirement for substantial future capital to fund development."]
What changed in the latest 10-Q
AI-assisted comparison of SYRE's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05) adds reference to Form 10-K filed on February 19, 2026 (vs. February 27, 2025 in older filing)
- Newer filing reports SPY001 Part A topline induction data announced in April 2026
- Newer filing reports initial topline data expected for SPY002 mid-2026 and SPY003 in third quarter 2026
- Newer filing states RA sub-study has completed enrollment ahead of schedule with topline data expected in Q3 2026
- Newer filing adds detail that SPY001 Phase 1 study is now complete
- Newer filing includes Figure 2 showing SKYLINE trial design with detailed endpoint information
- Newer filing includes Figure 3 showing SKYWAY trial design with detailed endpoint information
- Removed:
- Older filing contains detailed section on 'Acquisition of Pre-Merger Spyre' describing acquisition on June 22, 2023, and related license agreements—this section is entirely absent from newer filing
- Older filing contains detailed description of how the company was reshaped into clinical stage biotech following Asset Acquisition—this narrative is removed in newer filing
- Older filing's overview describes engineered modifications to Fc domain and anticipated less frequent administration—this technical detail is not present in newer filing's overview
- Older filing references 'initiated SKYLINE Phase 2 platform study' and 'initiated SKYWAY basket study'—newer filing refers to them as already-initiated programs with specific enrollment/data updates
- Reworded:
- Newer filing: quarterly period ended March 31, 2026 vs. older filing: September 30, 2025
- Newer filing describes company as 'pioneering long-acting antibodies' vs. older filing's more technical description of 'engineered with the aim to bind potently'
- Newer filing uses 'subjects' terminology consistently vs. older filing uses 'patients'
- Newer filing states Part A enrollment 'has completed' vs. older filing stating enrollment 'is currently enrolling subjects into the SPY001 and SPY002 arms'
- Newer filing Part A describes 'initial SPY001 Part A topline induction data announced in April 2026' vs. older filing stating induction data expected in 2026 without timing
- Newer filing adds specific pipeline figure and trial design figures with endpoints labeled vs. older filing references table without figures provided in excerpt
- Newer filing specifies SKYLINE consists of 'six investigational agents in total' vs. older filing saying 'six active investigational agents in total'
- Notes:
- Older filing text is truncated at end ('with SPY00'), limiting full comparison of later sections
- The newer filing excerpt ends mid-sentence on SPY001 description, preventing complete comparison of that drug's details
Risk Factors
- Added:
- Risk factor added (filed 2026-05-05): 'We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.'
- Risk factor added (filed 2026-05-05): 'The intellectual property landscape around engineered antibodies is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.'
- Risk factor added (filed 2026-05-05): 'Our expanding use of AI exposes us to operational, regulatory, legal, and ethical risks that could adversely affect our business, reputation, financial condition, and results of operations.'
- Removed:
- Risk factor removed (filed 2025-11-04): Language regarding 'nonclinical' stages was replaced with 'clinical and preclinical' stages in the first Discovery, Development and Commercialization risk factor.
- Risk factor removed (filed 2025-11-04): 'Our technology licensed from various third parties may be subject to retained rights.' was expanded in newer filing (filed 2026-05-05) to include additional language about failure to comply with license obligations and disruptions to business relationships.
- Risk factor removed (filed 2025-11-04): 'We may be impacted by security or data breaches or other improper access to our data.' was expanded in newer filing (filed 2026-05-05) to 'We may be impacted by information security incidents, cybersecurity or data breaches or other improper access to our data that could have a negative impact on our business or reputation.'
- Reworded:
- Filed 2026-05-05: 'clinical and nonclinical stages' changed to 'clinical and preclinical stages'
- Filed 2026-05-05: 'delays or failures in achieving alignment with regulatory authorities on trial designs and interpretation of data and its sufficiency to support safety and efficacy' changed to 'delays or failures in achieving alignment with regulatory authorities on interpretation of data and its sufficiency to support approval'
- Filed 2026-05-05: 'unanticipated drug supply disruptions' changed to 'or supply challenges'
- Filed 2026-05-05: 'projected development goals' changed to 'development goals'
- Filed 2026-05-05: 'intraportfolio' changed to 'intra-portfolio' (hyphenation change)
- Filed 2026-05-05: 'they face third-party program competition' changed to 'may face third-party program competition'
- Filed 2026-05-05: 'Our technology licensed from various third parties may be subject to retained rights.' expanded to include 'or may be affected by failure to comply with obligations in license agreements or other disruptions to business relationships with licensors resulting in loss of license rights that are important to our business.'
- Notes:
- The older filing text was truncated at the end of the 'Risks Related to Our Common Stock' section, preventing complete comparison of that section and any subsequent risk factors.
- The newer filing text was also truncated at the same point, making full comparison impossible for later sections.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 42 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 17 sells ($6M) — 3 selling insiders
- Last 90 days · read to 2026-10-040 buys · 42 sells ($17M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 78 sells ($438M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SYRE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding SYRE as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 22,899,808
- Reported value $2,033,044,953
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SYRE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SYRE had 12,129,443 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
SYRE had 13.8% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.58 days to cover at the same settlement.
- Reported short interest (shares) 12,129,443
- Short interest (% of shares outstanding) 13.8%
- Prior settlement (shares) 11,859,975
- Reported change 2.27%
- Days to cover (reported) 11.58
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Johnson & Johnson (JNJ)
- Takeda Pharmaceutical (TAK)
- Eli Lilly (LLY)
- Roivant Sciences (ROIV)
- Prometheus Biosciences (acquired by MRK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SYRE vs…
SPYRE THERAPEUTICS INC is found in…
SYRE ranks in…
Frequently asked questions
What does SPYRE THERAPEUTICS INC (SYRE) do?
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation, extended half-life antibody therapies for inflammatory bowel disease (IBD) and other immune-mediated conditions. The company utilizes a strategy of creating optimized monotherapies and fixed-dose combinations to improve potency, selectivity, and patient treatment experiences.
What sector is SPYRE THERAPEUTICS INC (SYRE) in?
SPYRE THERAPEUTICS INC (SYRE) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are SPYRE THERAPEUTICS INC's (SYRE) competitors?
Notable peers of SPYRE THERAPEUTICS INC (SYRE) include AbbVie, Johnson & Johnson, Takeda Pharmaceutical, Eli Lilly and Roivant Sciences. This peer set is informational only — not financial advice.
Is SPYRE THERAPEUTICS INC (SYRE) overbought or oversold right now?
SPYRE THERAPEUTICS INC (SYRE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SYRE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.